Hair

The document reviews multiple studies on hair disorders and treatments, highlighting significant findings. A study on alopecia areata (AA) in Australia with 337 patients revealed substantial impacts on quality of life, especially with extensive hair loss. Baricitinib treatment for severe AA showed that benefits were often lost after withdrawal, but over half regained response after 36 weeks of retreatment. Gender-affirming hormone therapy affected hair differently, with feminizing hormones increasing hair count and masculinizing hormones causing thinning. Low-dose oral minoxidil improved hair length and density in short anagen syndrome. The THRIVE-AA trials with 1,220 patients confirmed the safety of deuruxolitinib for AA. A study on scalp seborrheic dermatitis found Shampoo A more effective in reducing greasiness and pruritis than Shampoo B. Additionally, processed autologous cellular micrografts were noted for their simplicity and cost-effectiveness in treating androgenetic alopecia. A retrospective analysis of 663 patients with frontal fibrosing alopecia found minoxidil monotherapy more effective than androgen-directed therapies. Lastly, telogen effluvium was identified as a precursor to male pattern baldness in a study of 220 males.